Table 2 Clinical factors predicting OS in patients with residual nasopharyngeal carcinoma after IMRT in the training cohort

Age (years)

45.9 ± 11.6

1.042 (1.014– 1.071)

0.003^a

 ≥ 60

20 (11.6%)

3.480 (1.738–6.966)

 < 0.001^a

2.829 (1.394–5.741)

0.004^b

 < 60

153 (88.4%)

Reference

Reference

Gender

Male

127 (73.4%)

2.884 (1.132–7.352)

0.027^a

2.586 (1.005–6.654)

0.049^b

Female

46 (26.6%)

Reference

Reference

T category

T1

5 (2.9%)

 < 0.001 (< 0.001–NA)

0.972^a

T2

10 (5.8%)

1.217 (0.366–4.049)

0.749^a

T3

66 (38.2%)

0.788 (0.408–1.524)

0.480^a

T4

92 (53.2%)

Reference

N category

N0

15 (8.7%)

Reference

N1

71 (41.0%)

5.580 (0.749–41.555)

0.093^a

N2

68 (39.3%)

3.519 (0.459–26.997)

0.226^a

N3

19 (11.0%)

6.295 (0.756–52.422)

0.089^a

Stage

0.202^a

I

1 (0.6%)

 < 0.001 (< 0.001–NA)

0.980^a

II

10 (5.8%)

1.162 (0.352–3.836)

0.806^a

III

62 (35.8%)

0.611 (0.303–1.233)

0.169^a

IV

100 (57.8%)

Reference

NLR

2.5 (1.9–3.4)

1.114 (0.918–1.352)

0.275^a

 ≤ 2.9

107 (61.8%)

1.290 (0.668–2.491)

0.445^a

 > 2.9

66 (38.2%)

Reference

Hemoglobin (g/L)

135.1 ± 15.2

1.009 (0.987–1.031)

0.434^a

 ≤ 132.4

68 (39.3%)

Reference

0.220^a

 > 132.4

105 (60.7%)

1.510 (0.781–2.918)

Albumin (g/L)

43.8 ± 3.5

0.993 (0.906–1.089)

0.886^a

 ≤ 40.5

35 (20.2%)

2.244 (1.175–4.285)

0.012^a

Reference

 > 40.5

138 (79.8%)

Reference

0.477 (0.248–0.917)

0.026^b

Induction chemotherapy

Yes

56 (32.4%)

1.176 (0.623–2.221)

0.617^a

No

117 (67.6%)

Reference

Concurrent chemotherapy

Yes

163 (94.2%)

0.607 (0.216–1.704)

0.343^a

No

10 (5.8%)

Reference

Adjuvant chemotherapy

Yes

93 (53.8%)

1.015 (0.549–1.876)

0.962^a

No

80 (46.2%)

Reference